Interestingly, both CLEC9A and an “effector CD8 T cell” gene signature (Böttcher et al., 2018) correlated with “MHC class I (cross-)presentation-related” gene signatures more strongly in the low sGSN than in the high sGSN subgroup of STAD patients (Figure 6D). Here, CD8A is linked to gastric adenocarcinoma.